Dyslipidemias in chronic kidney disease: Current guidelines and future perspectives
نویسندگان
چکیده
منابع مشابه
Dyslipidemias in chronic kidney disease: Current guidelines and future perspectives
Introduction Dyslipidemia is a major problem in chronic kidney disease (CKD) and haemodialysis patients. Although there has been much progress and reduction in the prevalence of dyslipidemia after the Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel), there were few specifi...
متن کاملK/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease
........................................................................................................................... S10
متن کاملRelationship between chronic kidney disease and metabolic syndrome: current perspectives
Both metabolic syndrome (MetS) and chronic kidney disease (CKD) are increasing in incidence and lead to significant cardiovascular morbidity and mortality. The relationship between these two entities is complex. Individual components of the MetS are known risk factors for incident kidney disease, but it is not clear how the clustering of these components is linked to the development and progres...
متن کاملDown Syndrome: Current Status, Challenges and Future Perspectives
Down syndrome (DS) is a birth defect with huge medical and social costs, caused by trisomy of whole or part of chromosome 21. It is the most prevalent genetic disease worldwide and the common genetic cause of intellectual disabilities appearing in about 1 in 400-1500 newborns. Although the syndrome had been described thousands of years before, it was named after John Langdon Down who described ...
متن کاملAlzheimer's disease: current and future therapeutic perspectives.
1. A better understanding of the pathophysiology of AD has been made possible through population-based epidemiological studies, human genetic and post-mortem studies, leading to a number of testable hypothesis towards delaying progression. 2. A number of disease milestones have been identified as therapeutic targets, such as conversion from MCI to diagnosable dementia. 3. Clinicians caring for ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OA Nephrology
سال: 2013
ISSN: 2053-0293
DOI: 10.13172/2053-0293-1-1-479